Nyxoah SA
NYXH Healthcare Medical Instruments & Supplies
Nyxoah SA’s revenue for fiscal 2025 (year ended December 2025) was $11.3 million, up 131.7% from fiscal 2024. In the quarter to June 2026, revenue grew 486.6%, EPS fell 6.35%, free cash flow grew 4.01% and total debt rose 185.4%, each against the same quarter a year earlier. Revenue growth for five consecutive years.
Follow NYXH
Nyxoah SA (NYXH) P/E ratio
Nyxoah SA has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 17 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| STXS Stereotaxis Inc. compare | n/m |
| KRMD KORU Medical Systems, Inc. compare | n/m |
| MBOT Microbot Medical Inc. compare | n/m |
| NYXH Nyxoah SA | n/m |
| ZTEKF Zentek Ltd. compare | n/m |
| OSUR OraSure Technologies, Inc. compare | n/m |
| DXR Daxor Corporation compare | 4.7× |
| PDEX Pro-Dex, Inc. compare | 13.8× |
| UTMD Utah Medical Products, Inc. compare | 22.7× |
| Medical Instruments & Supplies industry median | 33.8× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)